Get the Stockscreener App
0.6994
0.66%
0.0046
Pre-market:
.71
0.0106
+1.52%
Bioatla Inc stock is traded at $0.6994, with a volume of 269.46K.
It is up +0.66% in the last 24 hours and up +1.67% over the past month.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
See More
Previous Close:
$0.6948
Open:
$0.7068
24h Volume:
269.46K
Relative Volume:
0.28
Market Cap:
$41.07M
Revenue:
-
Net Income/Loss:
$-123.46M
P/E Ratio:
-0.27
EPS:
-2.59
Net Cash Flow:
$-104.11M
1W Performance:
-7.97%
1M Performance:
+1.67%
6M Performance:
+43.85%
1Y Performance:
-63.57%
1-Day Range:
$0.674
$0.7202
1-Week Range:
$0.6611
$0.80
52-Week Range:
$0.2601
$2.525
Bioatla Inc Stock (BCAB) Company Profile
Name
Bioatla Inc
Sector
Industry
Phone
858-558-0708
Address
11085 TORREYANA ROAD, SAN DIEGO
Compare BCAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
0.6994 | 40.80M | 0 | -123.46M | -104.11M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Bioatla Inc Stock (BCAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Nov-13-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-15-22 | Initiated | JMP Securities | Mkt Outperform |
| May-05-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-21-22 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Jun-28-21 | Initiated | ROTH Capital | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | BTIG Research | Buy |
| Jan-11-21 | Initiated | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | JP Morgan | Overweight |
| Jan-11-21 | Initiated | Jefferies | Buy |
View All
Bioatla Inc Stock (BCAB) Latest News
Sentiment analysis tools applied to BioAtla Inc.Quarterly Profit Summary & Weekly Top Performers Watchlists - newser.com
Why BioAtla Inc. stock is favored by top institutionsJuly 2025 Summary & Expert Approved Trade Ideas - newser.com
Analyzing BioAtla Inc. with risk reward ratio chartsWeekly Profit Recap & Capital Efficiency Focused Ideas - newser.com
Is BioAtla Inc. a candidate for recovery play2025 Earnings Surprises & Verified High Yield Trade Plans - newser.com
BioAtla, Inc. (BCAB) stock forecast and price target - Yahoo! Finance UK
How supply chain issues affect BioAtla Inc. stockJuly 2025 Analyst Calls & Community Verified Swing Trade Signals - newser.com
Will BioAtla Inc. continue its uptrend2025 Earnings Surprises & Stepwise Entry and Exit Trade Signals - newser.com
Measuring BioAtla Inc.’s beta against major indices2025 Major Catalysts & Reliable Entry Point Trade Alerts - newser.com
BioAtla, Inc. (BCAB) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
What moving averages say about BioAtla Inc.Bond Market & Capital Efficiency Focused Ideas - newser.com
What to do if you’re stuck in BioAtla Inc.Earnings Growth Report & Technical Pattern Recognition Alerts - newser.com
Chart overlay techniques for tracking BioAtla Inc.Gold Moves & Low Drawdown Trading Strategies - newser.com
BioAtla’s Phase 1 Study on BA3182: A New Hope for Advanced Adenocarcinoma - MSN
BioAtla (BCAB) to Release Quarterly Earnings on Thursday - Defense World
BioAtla Stock Lost 7.0%, Buy Or Wait? - Trefis
Why BioAtla Inc. stock is a value investor pickWeekly Risk Summary & Advanced Technical Signal Analysis - fcp.pa.gov.br
Can BioAtla Inc. stock sustain institutional interest2025 Big Picture & Capital Protection Trade Alerts - Fundação Cultural do Pará
Bioatla Inc Stock (BCAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):